A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease

被引:33
|
作者
Woon, Claire [1 ]
Bielinski-Bradbury, Ashleigh [1 ]
O'Reilly, Karl [2 ]
Robinson, Paul [2 ]
机构
[1] Double Helix Consulting, Macclesfield, Cheshire, England
[2] Otsuka Pharmaceut Europe Ltd, Wexham, England
关键词
Autosomal dominant polycystic kidney disease; Disease progression; Systematic review; End stage renal disease; Prognostic indicators; FUNCTION DECLINE; BLOOD-PRESSURE; RENAL-FUNCTION; EXTRARENAL MANIFESTATIONS; SIROLIMUS THERAPY; SURROGATE MARKER; DANISH PATIENTS; MUTATED GENE; CYST GROWTH; VOLUME;
D O I
10.1186/s12882-015-0114-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterised by progressive renal cyst formation leading to renal failure in the majority of patients. The likelihood and rate of ADPKD progression is difficult to predict and there is a clear need to identify prognostic indicators that could be used to anticipate ADPKD progression, to aid the management of patients in clinical practice. Methods: A systematic literature review was conducted to identify publications detailing the natural history of ADPKD, including diagnosis, prognosis and progression. Publications were identified and filtered, and data were extracted, based on a predefined research protocol. Results: The review identified 2799 journal articles and 444 conference abstracts; 254 articles, including observational studies, clinical trials and reviews, proceeded to data extraction. Disease progression was associated with a variety of prognostic indicators, most commonly age and total kidney volume (TKV). In the identified clinical trials, the absence of a consistent measure of disease progression led to variation in the primary endpoints used. Consequently, there was difficulty in consistently and effectively demonstrating and comparing the efficacy of investigational treatments across studies. More consistency was found in the observational studies, where disease progression was most frequently measured by TKV and glomerular filtration rate. Conclusions: This systematic review identified age and TKV as the most commonly cited prognostic indicators in the published ADPKD literature. It is envisaged that this review may inform future research, trial design and predictive models of ADPKD natural history, helping to optimise patient care.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Interventions for preventing the progression of autosomal dominant polycystic kidney disease
    St Pierre, Kitty
    Cashmore, Brydee A.
    Bolignano, Davide
    Zoccali, Carmine
    Ruospo, Marinella
    Craig, Jonathan C.
    Strippoli, Giovanni F. M.
    Mallett, Andrew J.
    Green, Suetonia C.
    Tunnicli, David J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (10):
  • [32] Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Norman, Jill
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (10): : 1327 - 1336
  • [33] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Blair, Hannah A.
    DRUGS, 2019, 79 (03) : 303 - 313
  • [34] How to identify the rapid progression patients in the autosomal dominant polycystic kidney disease?
    Le Meur, Y.
    Fartoux, L.
    NEPHROLOGIE & THERAPEUTIQUE, 2016, 12 : S13 - S15
  • [35] Cardiovascular Involvement in Patients with Autosomal Dominant Polycystic Kidney Disease: A Review
    Pietrzak-Nowacka, Maria
    Safranow, Krzysztof
    Plonska-Gosciniak, Edyta
    Nowacki, Adam
    Pozniak, Piotr
    Gutowski, Piotr
    Ciechanowski, Kazimierz
    KIDNEY & BLOOD PRESSURE RESEARCH, 2024, 49 (01): : 9 - 19
  • [36] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Blair, Hannah A.
    Keating, Gillian M.
    DRUGS, 2015, 75 (15) : 1797 - 1806
  • [37] Review of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Baur, Brian P.
    Meaney, Calvin J.
    PHARMACOTHERAPY, 2014, 34 (06): : 605 - 616
  • [38] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Hannah A. Blair
    Gillian M. Keating
    Drugs, 2015, 75 : 1797 - 1806
  • [39] Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
    Hannah A. Blair
    Drugs, 2019, 79 : 303 - 313
  • [40] The impact of asymptomatic kidney stones on disease progression in autosomal dominant polycystic kidney disease
    Elcioglu, Omer Celal
    Yatci, Beyza
    Ozturk, Burak Baris
    Mirioglu, Safak
    Gursu, Meltem
    Kazancioglu, Rumeyza
    BMC NEPHROLOGY, 2025, 26 (01)